Antimicrobial therapies – such as antivirals and antibiotics – have played an essential role in the treatment of infections in humans and animals and have significantly improved public health for the last 100 years. Without antimicrobials, serious infections like pneumonia and tuberculosis could not be treated, complex medical interventions - such as organ transplantations – would not be possible due to the high risk of hospital acquired infections, and care of premature babies would be a serious challenge.
New Financial Arrangement to Improve Sustainability, Quality and Global Reach of WHO Prequalification of Medical Products
30 SEPTEMBER 2016 ¦ GENEVA – The World Health Organization (WHO), industry groups and key partners have agreed on a new financing arrangement to ensure the financial sustainability and quality of WHO’s prequalification programme in the coming years. The arrangement is based on an improved fee structure that aims to make the programme better equipped to address current global quality challenges in the medical products area, to lay the ground for strengthening and expanding services provided, and to improve financial predictability and transparency.
Antimicrobial Resistance: How to Foster Innovation, Access and Appropriate Use of Antibiotics? A Joint Technical Symposium by WHO, WIPO and WTO
Antimicrobial resistance is one of the most pressing challenges for humanity. It affects all areas of health, involves many sectors and has an impact on the whole of society. Increasing resistance threatens to roll back the achievements of modern medicine as many medicinal procedures rely on effective antibiotics. Antibiotics, more than other medicines, can be considered a public good for which society has a collective responsibility. The Symposium will offer a forum to exchange views and experiences, to achieve a better understanding of the global challenge of antimicrobial resistance and to envisage possible ways forward.
Date: 25 October 2016 Place: WIPO Headquarters, Geneva, Switzerland
Two innovative technologies for early infant diagnosis of HIV newly prequalified by WHO will allow many more infants to be diagnosed quickly and placed on life-saving treatment.
The products, Alere™ q HIV-1/2 Detect (made by Alere Technologies GmbH) and Xpert® HIV-1 Qual Assay (made by Cepheid AB) can be used to diagnose infants in as little as an hour, instead of sending a sample to a laboratory, which can take weeks or months to return a result.
26 - 27 October 2016
Global Vaccines Safety Initiative Annual Meeting
27 - 28 October 2016
40th ATC-DDD meeting of the WHO International Working Group for Drug Statistics
14 - 18 November 2016
HQ workshop on sensitization towards Quality Management Systems for National Regulatory Authorities, AFRO